These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15208495)

  • 1. Six month follow-up after 111In-DTPA-octreotide therapy in patients with progressive radioiodine non-responsive thyroid cancer: a pilot study.
    Stokkel MP; Verkooijen RB; Bouwsma H; Smit JW
    Nucl Med Commun; 2004 Jul; 25(7):683-90. PubMed ID: 15208495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy.
    Capello A; Krenning E; Bernard B; Reubi JC; Breeman W; de Jong M
    Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1288-95. PubMed ID: 16021448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experience with indium-111 and yttrium-90-labeled somatostatin analogs.
    Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Burggasser G; Andreae F; Kurtaran A; Dudczak R
    Curr Pharm Des; 2002; 8(20):1781-807. PubMed ID: 12171531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of combined imaging in metastatic medullary thyroid carcinoma: 111In-DTPA-octreotide and 131I/123I-MIBG as predictors for radionuclide therapy.
    Gao Z; Biersack HJ; Ezziddin S; Logvinski T; An R
    J Cancer Res Clin Oncol; 2004 Nov; 130(11):649-56. PubMed ID: 15300425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls.
    Beukhof CM; Brabander T; van Nederveen FH; van Velthuysen MF; de Rijke YB; Hofland LJ; Franssen GJH; Fröberg LAC; Kam BLR; Visser WE; de Herder WW; Peeters RP
    BMC Cancer; 2019 Apr; 19(1):325. PubMed ID: 30953466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptide receptor radionuclide therapy in vitro using [111In-DTPA0]octreotide.
    Capello A; Krenning EP; Breeman WA; Bernard BF; de Jong M
    J Nucl Med; 2003 Jan; 44(1):98-104. PubMed ID: 12515882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 111In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors.
    Forssell-Aronsson EB; Nilsson O; Bejegård SA; Kölby L; Bernhardt P; Mölne J; Hashemi SH; Wängberg B; Tisell LE; Ahlman H
    J Nucl Med; 2000 Apr; 41(4):636-42. PubMed ID: 10768564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of 111In-DOTA-lanreotide and 111In-DOTA-DPhe1-Tyr3-octreotide in differentiated thyroid cancer: results of in vitro binding studies and in vivo comparison with 18F-FDG PET.
    Rodrigues M; Traub-Weidinger T; Leimer M; Li S; Andreae F; Angelberger P; Dudczak R; Virgolini I
    Eur J Nucl Med Mol Imaging; 2005 Oct; 32(10):1144-51. PubMed ID: 15909194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.
    Barone R; Walrand S; Konijnenberg M; Valkema R; Kvols LK; Krenning EP; Pauwels S; Jamar F
    Nucl Med Commun; 2008 Mar; 29(3):283-90. PubMed ID: 18349800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The therapeutic value of SST-A octreotide alone or with adjuvant treatment in patients with advanced medullary thyroid carcinoma and positive (111)In-octreotide scan.
    Vainas I; Drimonitis A; Boudina M; Kaprara A; Iakovou I; Salem N; Koussis C
    Hell J Nucl Med; 2005; 8(1):43-7. PubMed ID: 15886753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid carcinoma.
    Teunissen JJ; Kwekkeboom DJ; Kooij PP; Bakker WH; Krenning EP
    J Nucl Med; 2005 Jan; 46 Suppl 1():107S-14S. PubMed ID: 15653659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is there a role for peptide receptor radionuclide therapy in medullary thyroid cancer?
    Vaisman F; Rosado de Castro PH; Lopes FP; Kendler DB; Pessoa CH; Bulzico DA; de Carvalho Leal D; Vilhena B; Vaisman M; Carneiro M; Corbo R
    Clin Nucl Med; 2015 Feb; 40(2):123-7. PubMed ID: 25546220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
    De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
    Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake.
    Bernard BF; Krenning EP; Breeman WA; Rolleman EJ; Bakker WH; Visser TJ; Mäcke H; de Jong M
    J Nucl Med; 1997 Dec; 38(12):1929-33. PubMed ID: 9430472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas.
    Boni G; Ferdeghini M; Bellina CR; Matteucci F; Castro Lopez E; Parenti G; Canapicchi R; Bianchi R
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):90-3. PubMed ID: 9002759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatostatin receptor imaging in intracranial tumours.
    Schmidt M; Scheidhauer K; Luyken C; Voth E; Hildebrandt G; Klug N; Schicha H
    Eur J Nucl Med; 1998 Jul; 25(7):675-86. PubMed ID: 9662588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of differentiated thyroid cancer with rising thyroglobulin and negative diagnostic radioiodine whole body scan.
    Chao M
    Clin Oncol (R Coll Radiol); 2010 Aug; 22(6):438-47. PubMed ID: 20561773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of radioactive somatostatin and its analogues in the control of tumor growth.
    Krenning EP; Valkema R; Kooij PP; Breeman WA; Bakker WH; de Herder WW; van Eijck CH; Kwekkeboom DJ; de Jong M; Jamar F; Pauwels S
    Recent Results Cancer Res; 2000; 153():1-13. PubMed ID: 10626285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiopeptide transmitted internal irradiation of non-iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using.
    Waldherr C; Schumacher T; Pless M; Crazzolara A; Maecke HR; Nitzsche EU; Haldemann A; Mueller-Brand J
    Nucl Med Commun; 2001 Jun; 22(6):673-8. PubMed ID: 11403179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indium-111 octreotide scintigraphy for the detection of non-functioning metastases from differentiated thyroid cancer: diagnostic and prognostic value.
    Stokkel MP; Verkooijen RB; Smit JW
    Eur J Nucl Med Mol Imaging; 2004 Jul; 31(7):950-7. PubMed ID: 14991244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.